T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer
The FDA cleared a second Phase 2 study of MT027, an investigational allogeneic CAR-T, in brain metastases from lung and breast cancer.
TL;DR
- T-MAXIMUM said FDA cleared MT027 for a Phase 2 study in brain metastases from lung and breast cancer.
- The company described this as MT027’s second FDA-cleared Phase 2 program, after recurrent glioblastoma.
- A clearance to begin a study is not evidence that the therapy is effective or an approval for marketing.
T-MAXIMUM Pharmaceutical said on October 12 that the U.S. Food and Drug Administration cleared it to initiate a Phase 2 clinical study of MT027 in patients with brain metastases from lung or breast cancer. The company describes MT027 as an investigational, B7-H3-targeted allogeneic CAR-T therapy. [1] [2]
The company said this is MT027’s second FDA-cleared Phase 2 study. It previously received clearance for a Phase 2 study in recurrent glioblastoma and holds Orphan Drug and Fast Track designations, according to the announcement and separate BioPharm International coverage. [1] [2]
The new study concerns secondary brain tumors arising from lung or breast cancer. The cited announcement does not provide a trial registry number, enrollment target, start date, or a complete protocol description for this study. [1] [2]
Regulatory clearance to start a clinical study is not evidence of clinical benefit and is not marketing authorization. Safety and efficacy in the specified patient groups remain questions for the planned study and subsequent review. [1] [2]
Why it matters
The clearance expands clinical testing of an allogeneic CAR-T approach into brain metastases from two common solid tumors, while providing no efficacy conclusion yet.
Editor's note
The study clearance and prior designations are reported by the company and BioPharm International. The new program’s registry details were not disclosed in the cited reports; no treatment advice is offered.